$Entera Bio(ENTX.US)$Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome 1 MINUTE AGO, 8:00 AM EDT VIA GLOBENEWSWIRE
$Entera Bio(ENTX.US)$Lets do the house keeping first! Have until 12/26/23 For trade over dollar 30 days to regain compliance! NOT a chance. So R/S may happen? But they could also get 1 more 180 day extension? Waiting to see? Now to the WATCHING REMINDER! And i will just give you the company’s words for this! PAY ATTENTION TO LAST SENTENCE ! (((((( EB612: First Oral PTH(1-34) Peptide Replacement Therapy Tablets for Hypoparathyroidism EB612, is the first oral formu...
$Entera Bio(ENTX.US)$ EB613: First Oral PTH(1-34) Daily Osteoanabolic Tablets for Osteoporosis EB613 (oral PTH (1-34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for osteoporosis. Entera is prepared to initiate a pivotal phase 3 study in post-menopausal women with high-risk osteoporosis and no prior fracture. Entera successfully completed a phase 2, 6-month, 161-patient, placebo-con...
diamonds : 請問,ENDPQ重組後,持有的股票還能有效嗎?